Efficacy and safety of the freeze-dried cultured human keratinocyte lysate, LyphoDermtm 0.9%, in the treatment of hard-to-heal venous leg ulcers
- 1 March 2005
- journal article
- clinical trial
- Published by Wiley in Wound Repair and Regeneration
- Vol. 13 (2) , 138-147
Abstract
LyphoDerm (XCELLentis, Belgium) is an end-sterilized, freeze-dried lysate from cultured allogeneic epidermal keratinocytes, formulated into a hydrophilic gel. Its efficacy and safety were evaluated, in combination with standard care (hydrocolloid dressing and compression therapy), in 194 patients suffering from hard-to-heal (lasting more than 6 weeks and not responding to conventional therapy) venous leg ulcers. Two control groups received standard care, with or without vehicle, respectively. Patients had a median age of 67.5 years and the majority were females (61%). The median duration of the ulcer was 43 weeks and in 39% of the subjects it had been present for more than 1 year. Thirty-eight percent of the patients in the standard care + LyphoDerm group had complete ulcer healing within 24 weeks (primary end point) compared to 27% of patients in the standard care + vehicle pooled groups (P = 0.114) in the "as treated" intent-to-treat cohort (37% vs. 27% in the "as randomized intent-to-treat cohort; p = 0.137). In the subgroup of patients with enlarging ulcers, the difference between the two groups was significant (30% vs. 11%; p = 0.024 in the "as treated" intent-to-treat cohort and 31% vs. 9%; p = 0.005 in the "as randomized" intent-to-treat cohort). LyphoDerm was well tolerated and safe, and no differences in the frequency of adverse events were noted between the treatment groups. Although the primary objective of the study was not achieved, the exploratory analysis carried out in patients with enlarging ulcers suggests that LyphoDerm could offer a new prospect for the treatment of patients with venous ulcers that may prove to be a significant adjunct to the overall provision of care.Keywords
This publication has 21 references indexed in Scilit:
- The accuracy of venous leg ulcer prognostic models in a wound care systemWound Repair and Regeneration, 2004
- Randomized trial of four‐layer and two‐layer bandage systems in the management of chronic venous ulcerationWound Repair and Regeneration, 2003
- Maggot Therapy for Treating Diabetic Foot Ulcers Unresponsive to Conventional TherapyDiabetes Care, 2003
- A bilayered living skin construct (APLIGRAF®) accelerates complete closure of hard‐to‐heal venous ulcersWound Repair and Regeneration, 1999
- Lyophilized Keratinocyte Cell Lysates Contain Multiple Mitogenic Activities and Stimulate Closure of Meshed Skin Autograft-Covered Burn Wounds with Efficiency Similar to That of Fresh Allogeneic Keratinocyte CulturesPlastic and Reconstructive Surgery, 1996
- The prevalence of chronic lower-limb ulceration has been underestimated: Results of a validated population questionnaireBritish Journal of Surgery, 1996
- Lysates from Cultured Allogeneic Keratinocytes Stimulate Wound Healing after TympanoplastyActa Oto-Laryngologica, 1996
- A study of the impact of leg ulcers on quality of life: Financial, social, and psychologic implicationsJournal of the American Academy of Dermatology, 1994
- Leg ulcersJournal of the American Academy of Dermatology, 1991
- Treatment of chronic venous ulcers with sheets of cultured allogenic keratinocytesBritish Journal of Dermatology, 1987